Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-484-3300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$310,000.00
Profitability
Miscellaneous
Employees89
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) issued its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.09. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
2 Wall Street analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $18.00 to $25.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $21.50 in the next year. This suggests a possible upside of 145.7% from the stock's current price. View Analyst Price Targets for Xenon Pharmaceuticals.
What is the consensus analysts' recommendation for Xenon Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenon Pharmaceuticals.
Has Xenon Pharmaceuticals been receiving favorable news coverage?
Headlines about XENE stock have been trending very negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Xenon Pharmaceuticals.
Are investors shorting Xenon Pharmaceuticals?
Xenon Pharmaceuticals saw a decrease in short interest in September. As of September 30th, there was short interest totalling 277,900 shares, a decrease of 16.0% from the August 30th total of 330,900 shares. Based on an average daily volume of 45,600 shares, the short-interest ratio is presently 6.1 days. Approximately 1.2% of the company's shares are short sold. View Xenon Pharmaceuticals' Current Options Chain.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Phibro Animal Health (PAHC), ANI Pharmaceuticals (ANIP), Spectrum Pharmaceuticals (SPPI), Athenex (ATNX), Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), Amneal Pharmaceuticals (AMRX), ZEALAND PHARMA/S (ZEAL), G1 Therapeutics (GTHX), CannTrust (CNTTF), Endo International (ENDP), Cara Therapeutics (CARA), Emisphere Technologies (EMIS) and Omeros (OMER).
What other stocks do shareholders of Xenon Pharmaceuticals own?
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Simon Neil Pimstone, Chief Executive Officer & Director
- Ian C. Mortimer, President, Chief Financial Officer & Secretary
- Ernesto Aycardi, Chief Medical Officer
- Robin Sherrington, Executive VP-Business & Corporate Development
- Charles J. Cohen, Vice President-Biological Sciences
Who are Xenon Pharmaceuticals' major shareholders?
Xenon Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (2.34%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Which institutional investors are buying Xenon Pharmaceuticals stock?
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $8.75.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $225.53 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-34,500,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.View Additional Information About Xenon Pharmaceuticals.
What is Xenon Pharmaceuticals' official website?
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
